Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.61%
1,044.68
-6.39
-0.61%
—1,051.071,046.551,057.891,043.06——
SIXC
Communications
SIXC
Communications
SIXC
-2.38%
569.36
-13.89
-2.38%
—583.25583.25583.25568.79——
SIXE
Energy
SIXE
Energy
SIXE
+1.68%
1,296.57
+21.36
+1.68%
—1,275.211,277.701,302.121,275.67——
SIXI
Industrials
SIXI
Industrials
SIXI
-2.26%
1,628.49
-37.62
-2.26%
—1,666.111,658.231,661.311,626.65——
SIXM
Financials
SIXM
Financials
SIXM
-0.53%
605.62
-3.24
-0.53%
—608.86607.95610.78603.35——
SIXR
Staples
SIXR
Staples
SIXR
-0.44%
821.46
-3.67
-0.44%
—825.13825.12832.42821.09——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.12%
198.06
-0.24
-0.12%
—198.30198.30199.82197.25——
SIXT
Technology
SIXT
Technology
SIXT
-2.90%
2,675.94
-80.06
-2.90%
—2,756.002,727.872,729.882,674.29——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
918.41
+1.46
+0.16%
—916.95917.31921.78912.88——
SIXV
Health care
SIXV
Health care
SIXV
-0.31%
1,475.20
-4.55
-0.31%
—1,479.751,478.541,486.621,474.41——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.67%
2,201.77
-37.31
-1.67%
—2,239.082,228.382,241.812,199.73——
TEVA:TLV
Teva Pharmaceutical Industries Ltd
ILA 9,225.00
-0.67%
(-62.00) 1D
Mar 26, 5:26:00 PM GMT+2  ·   ILA
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Open
ILA 9,186.00
High
ILA 9,265.00
Low
ILA 9,055.00
Mkt. cap
34.99B
Avg. vol.
1.04M
Volume
1.35M
P/E ratio
24.39
52-wk high
ILA 11,350.00
52-wk low
ILA 4,865.00
EPS
ILA 3.78
Shares outstanding
1.16B
No. of employees
32K
News stories
From sources across the web
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Ltd
CEORichard Francis
Employees32K
FoundedFeb 13, 1944
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
3.89B
4.18B
4.48B
4.71B
Cost of goods sold
2.01B
2.07B
2.18B
2.06B
Cost of revenue
2.01B
2.07B
2.18B
2.06B
Research and development expenses
247.00M
244.00M
256.00M
267.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
919.00M
959.00M
973.00M
1.12B
Operating expense
1.17B
1.21B
1.24B
1.37B
Total operating expenses
3.18B
3.28B
3.41B
3.43B
Operating income
709.00M
894.00M
1.07B
1.28B
Other non operating income
47.00M
-90.00M
-27.00M
-
EBT including unusual items
294.00M
204.00M
648.00M
90.00M
EBT excluding unusual items
482.00M
643.00M
832.00M
1.08B
Income tax expense
74.00M
-78.00M
214.00M
-390.00M
Effective tax rate
25.17%
-38.24%
33.02%
-433.33%
Other operating expenses
2.00M
5.00M
9.00M
-17.00M
Net income
214.00M
282.00M
433.00M
480.00M
Net profit margin
5.50%
6.75%
9.67%
10.19%
Earnings per share
0.52
0.66
0.78
0.96
Interest and investment income
-
-
-
92.00M
Interest expense
-212.00M
-220.00M
-205.00M
-280.00M
Net interest expenses
-212.00M
-220.00M
-205.00M
-188.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
953.00M
1.14B
1.32B
1.54B
Gain or loss from assets sale
-
-2.00M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer